Positive Data connected Lilly Psoriasis Drug Zacks.com The New England writing of Medicine recently published new phase II collection on Eli Lilly and Company's (LLY) psoriasis candidate, ixekizumab (formerly known As LY2439821). Results from the study, conducted with 142 patients suffering from ... and more » Link To Article
No comments:
Post a Comment